Detail akcie Nanobiotix online

Business Summary: Nanobiotix SA is a France-based nanomedicine company. The Company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. It develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The Company's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, Nanobiotix SA revenues increased from -EUR11.6M to EUR7.8M. Net loss applicable to common stockholders decreased 65% to EUR24M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects research and development of product candidates segment loss decrease of 84% to EUR10.8M.